Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
2.780
-0.060 (-2.11%)
At close: Feb 21, 2025, 4:00 PM
2.870
+0.090 (3.24%)
After-hours: Feb 21, 2025, 7:55 PM EST
Perspective Therapeutics Employees
As of December 31, 2023, Perspective Therapeutics had 119 total employees, including 116 full-time and 3 part-time employees. The number of employees increased by 53 or 80.30% compared to the previous year.
Employees
119
Change
53
Growth
80.30%
Revenue / Employee
$13,084
Profits / Employee
-$536,008
Market Cap
186.54M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
CATX News
- 1 day ago - Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results - GlobeNewsWire
- 17 days ago - Perspective Therapeutics to Participate in Upcoming February Investor Conferences - GlobeNewsWire
- 4 weeks ago - Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium - GlobeNewsWire
- 6 weeks ago - Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM - Seeking Alpha
- 2 months ago - Perspective Therapeutics: Definitely Not Looking Overvalued Now - Seeking Alpha
- 3 months ago - Perspective Therapeutics to Participate in Upcoming Investor Conferences in December - GlobeNewsWire
- 3 months ago - Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium - GlobeNewsWire